Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Código QR

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Guardado en:

Detalles Bibliográficos
Autores principales:	Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Carla L. Alves, et al.
Publicado: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Olga Martínez-Sáez, et al.
Publicado: (2021)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Abeer J. Al-Qasem, et al.
Publicado: (2021)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Lindsey R. Pack, et al.
Publicado: (2021)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Erin R. Scheidemann, et al.
Publicado: (2021)

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Yibo Xue, et al.
Publicado: (2019)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
por: Luigi Formisano, et al.
Publicado: (2019)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Jennifer Y. Ge, et al.
Publicado: (2020)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
por: Emily Jiggens, et al.
Publicado: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Fabin Dang, et al.
Publicado: (2021)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida M, et al.
Publicado: (2020)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
por: Jin Zhou, et al.
Publicado: (2017)

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
por: Tongzheng Liu, et al.
Publicado: (2017)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
por: Irina V. Kolyadina, et al.
Publicado: (2021)

Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke
por: Nina Privšek, et al.
Publicado: (2021)

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
por: Shuo Qie, et al.
Publicado: (2019)

A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition
por: Manuel Kaulich, et al.
Publicado: (2021)

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
por: Ying Ji, et al.
Publicado: (2020)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
por: Yibo Xue, et al.
Publicado: (2019)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
por: Thompson MR, et al.
Publicado: (2021)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
por: Andrea Magali González-Mora, et al.
Publicado: (2021)

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
por: Grzegorz Sarek, et al.
Publicado: (2010)

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
por: Gabriela M Wright, et al.
Publicado: (2021)

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
por: Lauren E. Stopfer, et al.
Publicado: (2020)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Smruthi Vijayaraghavan, et al.
Publicado: (2017)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
por: Jingyi Liu, et al.
Publicado: (2018)

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
por: Ang Gao, et al.
Publicado: (2018)

IgG4-related disease in endocrine practice
por: Agata Rzepecka, et al.
Publicado: (2018)

CDK6 inhibits white to beige fat transition by suppressing RUNX1
por: Xiaoli Hou, et al.
Publicado: (2018)

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
por: Sung Pil Hong, et al.
Publicado: (2019)

Endocrine today

Endocrine research
Publicado: (1984)

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
por: Qingfei Wang, et al.
Publicado: (2019)

Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
por: Muhammad Imtiaz Shafiq, et al.
Publicado: (2012)

Silencing CDK6-AS1 inhibits LPS-induced inflammatory damage in HK-2 cells
por: Wu Ling, et al.
Publicado: (2021)

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes
por: Mikkel G. Terp, et al.
Publicado: (2021)

Three decades of Cdk5
por: Ping-Chieh Pao, et al.
Publicado: (2021)

BMC endocrine disorders
Publicado: (2001)